Literature DB >> 23383365

Treatment of Budd-Chiari syndrome with a focus on transjugular intrahepatic portosystemic shunt.

Anders Bay Neumann1, Stine Degn Andersen, Dennis Tønner Nielsen, Peter Holland-Fischer, Hendrik Vilstrup, Henning Grønbæk.   

Abstract

AIM: To evaluate long-term complications and survival in patients with Budd-Chiari syndrome (BCS) referred to a Danish transjugular intrahepatic portosystemic shunt (TIPS) centre.
METHODS: Twenty-one consecutive patients from 1997-2008 were retrospectively included [15 women and 6 men, median age 40 years (range 17-66 years)]. Eighteen Danish patients came from the 1.8 million catchment population of Aarhus University Hospital and three patients were referred from Scandinavian hospitals. Management consisted of tests for underlying haematological, endocrinological, or hypercoagulative disorders parallel to initiation of specific treatment of BCS.
RESULTS: BCS was mainly caused by thrombophilic (33%) or myeloproliferative (19%) disorders. Forty-three percents had symptoms for less than one week with ascites as the most prevalent finding. Fourteen (67%) were treated with TIPS and 7 (33%) were manageable with treatment of the underlying condition and diuretics. The median follow-up time for the TIPS-treated patients was 50 mo (range 15-117 mo), and none required subsequent liver transplantation. Ascites control was achieved in all TIPS patients with a marked reduction in the dose of diuretics. A total of 14 TIPS revisions were needed, mostly of uncovered stents. Two died during follow-up: One non-TIPS patient worsened after 6 mo and died in relation to transplantation, and one TIPS patient died 4 years after the TIPS-procedure, unrelated to BCS.
CONCLUSION: In our BCS cohort TIPS-treated patients have near-complete survival, reduced need for diuretics and compared to historical data a reduced need for liver transplantation.

Entities:  

Keywords:  Ascites; Budd-Chiari syndrome; Myeloproliferative disorder; Thrombophilia; Thrombosis; Transjugular intrahepatic portosystemic shunt

Year:  2013        PMID: 23383365      PMCID: PMC3562725          DOI: 10.4254/wjh.v5.i1.38

Source DB:  PubMed          Journal:  World J Hepatol


  29 in total

1.  Revising consensus in portal hypertension: report of the Baveno V consensus workshop on methodology of diagnosis and therapy in portal hypertension.

Authors:  Roberto de Franchis
Journal:  J Hepatol       Date:  2010-06-27       Impact factor: 25.083

2.  Incidence of parenchymal liver diseases in Denmark, 1981 to 1985: analysis of hospitalization registry data. The Danish Association for the Study of the Liver.

Authors:  T P Almdal; T I Sørensen
Journal:  Hepatology       Date:  1991-04       Impact factor: 17.425

3.  Cause of portal or hepatic venous thrombosis in adults: the role of multiple concurrent factors.

Authors:  M H Denninger; Y Chaït; N Casadevall; S Hillaire; M C Guillin; A Bezeaud; S Erlinger; J Briere; D Valla
Journal:  Hepatology       Date:  2000-03       Impact factor: 17.425

4.  Budd-Chiari and inferior caval vein syndromes due to membranous obstruction of the liver veins: successful treatment with angioplasty and transcaval transjugular intrahepatic porto-systemic shunt.

Authors:  P Holland-Fischer; H Grønbaek; L Astrup; S Keiding; D Tønner Nielsen; H Vilstrup
Journal:  Scand J Gastroenterol       Date:  2004-10       Impact factor: 2.423

5.  The Budd-Chiari syndrome: correlation between hepatic scintigraphy and the clinical, radiological, and pathological findings in nineteen cases of hepatic venous outflow obstruction.

Authors:  A S Tavill; E J Wood; L Kreel; E A Jones; M Gregory; S Sherlock
Journal:  Gastroenterology       Date:  1975-03       Impact factor: 22.682

Review 6.  Hepatic outflow obstruction (Budd-Chiari syndrome). Experience with 177 patients and a review of the literature.

Authors:  J B Dilawari; P Bambery; Y Chawla; U Kaur; S R Bhusnurmath; H S Malhotra; G K Sood; S K Mitra; S K Khanna; B S Walia
Journal:  Medicine (Baltimore)       Date:  1994-01       Impact factor: 1.889

7.  Color Doppler imaging findings in patients with Budd-Chiari syndrome: correlation with venographic findings.

Authors:  P Millener; E G Grant; S Rose; A Duerinckx; V L Schiller; F N Tessler; R R Perrella; N Ragavendra
Journal:  AJR Am J Roentgenol       Date:  1993-08       Impact factor: 3.959

8.  Budd-Chiari syndrome: imaging with pathologic correlation.

Authors:  W J Miller; M P Federle; W H Straub; P L Davis
Journal:  Abdom Imaging       Date:  1993

9.  TIPS for acute and chronic Budd-Chiari syndrome: a single-centre experience.

Authors:  Andrea Mancuso; Konrad Fung; Maria Mela; John Tibballs; Anthony Watkinson; Andrew K Burroughs; David Patch
Journal:  J Hepatol       Date:  2003-06       Impact factor: 25.083

10.  The Budd-Chiari syndrome: outcome after treatment with the transjugular intrahepatic portosystemic shunt.

Authors:  Martin Rössle; Manfred Olschewski; Volker Siegerstetter; Elisabeth Berger; Katharina Kurz; Daniel Grandt
Journal:  Surgery       Date:  2004-04       Impact factor: 3.982

View more
  6 in total

1.  Accessory hepatic vein recanalization for treatment of Budd-Chiari syndrome due to long-segment obstruction of the hepatic vein: initial clinical experience.

Authors:  Yu Fei Fu; Hao Xu; Ke Zhang; Qing Qiao Zhang; Ning Wei
Journal:  Diagn Interv Radiol       Date:  2015 Mar-Apr       Impact factor: 2.630

2.  Budd-Chiari syndrome: consensus guidance of the Asian Pacific Association for the study of the liver (APASL).

Authors:  Akash Shukla; Ananta Shreshtha; Amar Mukund; Chhagan Bihari; C E Eapen; Guohong Han; Hemant Deshmukh; Ian Homer Y Cua; Cosmas Rinaldi Adithya Lesmana; Mamun Al Meshtab; Masayoshi Kage; Roongruedee Chaiteeraki; Sombat Treeprasertsuk; Suprabhat Giri; Sundeep Punamiya; Valerie Paradis; Xingshun Qi; Yasuhiko Sugawara; Zaigham Abbas; Shiv Kumar Sarin
Journal:  Hepatol Int       Date:  2021-07-08       Impact factor: 6.047

3.  Excellent long-term outcomes of endovascular treatment in budd-chiari syndrome with hepatic veins involvement: A STROBE-compliant article.

Authors:  Yonghua Bi; Hongmei Chen; Pengxu Ding; Pengli Zhou; Xinwei Han; Jianzhuang Ren
Journal:  Medicine (Baltimore)       Date:  2018-10       Impact factor: 1.817

4.  Evaluation of outcome from endovascular therapy for Budd-Chiari syndrome: a systematic review and meta-analysis.

Authors:  Gauri Mukhiya; Xueliang Zhou; Xinwei Han; Dechao Jiao; Gaurab Pokhrel; Yahua Li; Sita Pokhrel
Journal:  Sci Rep       Date:  2022-09-28       Impact factor: 4.996

Review 5.  Transjugular intrahepatic portosystemic shunt for Budd-Chiari syndrome: A comprehensive review.

Authors:  Riccardo Inchingolo; Alessandro Posa; Martin Mariappan; Tiago Kojun Tibana; Thiago Franchi Nunes; Stavros Spiliopoulos; Elias Brountzos
Journal:  World J Gastroenterol       Date:  2020-09-14       Impact factor: 5.742

6.  Transjugular intrahepatic portosystemic stent-shunt in the management of portal hypertension.

Authors:  Dhiraj Tripathi; Adrian J Stanley; Peter C Hayes; Simon Travis; Matthew J Armstrong; Emmanuel A Tsochatzis; Ian A Rowe; Nicholas Roslund; Hamish Ireland; Mandy Lomax; Joanne A Leithead; Homoyon Mehrzad; Richard J Aspinall; Joanne McDonagh; David Patch
Journal:  Gut       Date:  2020-02-29       Impact factor: 23.059

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.